Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business

Executive Summary

A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.

Advertisement

Related Content

European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
P&G Chooses Merck's Consumer Health Business In $4.2bn Deal
GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
P&G Extends Gum Repair Toothpaste Line As It Trims Production Footprint
P&G Goes Native In Acquisition That Aligns With Peltz' Recommendations

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel